These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 36848091)

  • 1. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
    Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
    JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of new blood pressure target for hypertensive patients in Taiwan according to the 2022 hypertension clinical practice guidelines of the Taiwan society of cardiology: a simulation modeling study.
    Liao CT; Toh HS; Yang CT; Hsu CY; Lee MC; Chang WT; Chen ZC; Chang HY; Strong C
    Hypertens Res; 2023 Jan; 46(1):187-199. PubMed ID: 36229527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.
    Bress AP; Bellows BK; King JB; Hess R; Beddhu S; Zhang Z; Berlowitz DR; Conroy MB; Fine L; Oparil S; Morisky DE; Kazis LE; Ruiz-Negrón N; Powell J; Tamariz L; Whittle J; Wright JT; Supiano MA; Cheung AK; Weintraub WS; Moran AE;
    N Engl J Med; 2017 Aug; 377(8):745-755. PubMed ID: 28834469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Intensive Blood Pressure Management.
    Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
    JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
    Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
    PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Intensive Versus Standard Blood Pressure Treatment in Older Patients With Hypertension in China.
    Fan J; Zheng W; Liu W; Xu J; Zhou L; Liu S; Bai J; Qi Y; Huang W; Liu K; Cai J
    Hypertension; 2022 Nov; 79(11):2631-2641. PubMed ID: 36177835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
    Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
    Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a population-based AAA screening program for men over 65 years old in Iran.
    Daroudi R; Shafe O; Moosavi J; Salimi J; Bayazidi Y; Zafarghandi MR; Maleki M; Moini M; Farshidmehr P; Sadeghipour P
    Cost Eff Resour Alloc; 2021 May; 19(1):29. PubMed ID: 33985531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
    JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment.
    Kaplan RI; De Moraes CG; Cioffi GA; Al-Aswad LA; Blumberg DM
    JAMA Ophthalmol; 2015 May; 133(5):560-7. PubMed ID: 25741886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Care Management to Reduce Disparities and Control Hypertension in Primary Care: A Cost-effectiveness Analysis.
    Hong JC; Padula WV; Hollin IL; Hussain T; Dietz KB; Halbert JP; Marsteller JA; Cooper LA
    Med Care; 2018 Feb; 56(2):179-185. PubMed ID: 29239999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
    Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
    Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
    Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
    Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.